These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33975404)

  • 21. Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post-administration by magnetic resonance imaging.
    Pritchard S; Glover M; Guthrie G; Brum J; Ramsey D; Kappler G; Thomas P; Stuart S; Hull D; Gowland P
    Pulm Pharmacol Ther; 2014 Feb; 27(1):121-6. PubMed ID: 23988443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion.
    Vaidyanathan S; Williamson P; Clearie K; Khan F; Lipworth B
    Am J Respir Crit Care Med; 2010 Jul; 182(1):19-24. PubMed ID: 20203244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HBO2 and cerebral palsy in children.
    Gottlieb SF; Neubauer RA
    Undersea Hyperb Med; 2007; 34(1):1-3; author reply 6. PubMed ID: 17393933
    [No Abstract]   [Full Text] [Related]  

  • 24. HBO2 and cerebral palsy in children.
    Marois P; Vanasse M
    Undersea Hyperb Med; 2007; 34(1):4-6; author reply 6. PubMed ID: 17393934
    [No Abstract]   [Full Text] [Related]  

  • 25. Inner and middle ear hyperbaric oxygen-induced barotrauma.
    Beuerlein M; Nelson RN; Welling DB
    Laryngoscope; 1997 Oct; 107(10):1350-6. PubMed ID: 9331312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Middle ear barotrauma in patients undergoing hyperbaric oxygen therapy.
    Blanshard J; Toma A; Bryson P; Williamson P
    Clin Otolaryngol Allied Sci; 1996 Oct; 21(5):400-3. PubMed ID: 8932942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral neuropathy may increase the risk for asymptomatic otic barotrauma during hyperbaric oxygen therapy: research report.
    Mozdzanowski C; Perdrizet GA
    Undersea Hyperb Med; 2014; 41(4):267-72. PubMed ID: 25109078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Middle ear barotrauma associated with hyperbaric oxygenation treatment.
    Igarashi Y; Watanabe Y; Mizukoshi K
    Acta Otolaryngol Suppl; 1993; 504():143-5. PubMed ID: 8470522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevention of middle ear barotrauma caused by hyperbaric oxygen].
    Lin YH
    Zhonghua Hu Li Za Zhi; 1993 Mar; 28(3):147-8. PubMed ID: 8334725
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of self-acupressure on middle ear barotrauma associated with hyperbaric oxygen therapy: A nonrandomized clinical trial.
    Chen JM; Lu ZN; Wu RW; Bi KW; Liu CT
    Medicine (Baltimore); 2021 Apr; 100(17):e25674. PubMed ID: 33907136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects.
    Eskiizmir G; Hirçin Z; Ozyurt B; Unlü H
    Eur J Clin Pharmacol; 2011 Jan; 67(1):19-23. PubMed ID: 21069518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective analysis of independent patient risk factors for middle ear barotrauma in a multiplace hyperbaric chamber.
    Commons KH; Blake DF; Brown LH
    Diving Hyperb Med; 2013 Sep; 43(3):143-7. PubMed ID: 24122189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of otoscan-assisted laser myringotomy in hyperbaric oxygen therapy.
    Bent JP; April MM; Ward RF; Packard AM
    Undersea Hyperb Med; 2000; 27(3):159-61. PubMed ID: 11191162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.
    Watanabe H; Foo TH; Djazaeri B; Duncombe P; Mackay IS; Durham SR
    Rhinology; 2003 Sep; 41(3):167-74. PubMed ID: 14579657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of oxymetazoline nose drops on acute sinusitis in the rabbit.
    Bende M; Fukami M; Arfors KE; Mark J; Stierna P; Intaglietta M
    Ann Otol Rhinol Laryngol; 1996 Mar; 105(3):222-5. PubMed ID: 8615587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis.
    Graf P; Enerdal J; Hallén H
    Arch Otolaryngol Head Neck Surg; 1999 Oct; 125(10):1128-32. PubMed ID: 10522506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complications and side effects of hyperbaric oxygen therapy.
    Plafki C; Peters P; Almeling M; Welslau W; Busch R
    Aviat Space Environ Med; 2000 Feb; 71(2):119-24. PubMed ID: 10685584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxymetazoline Applied Topically to the Nasal Mucosa Decreases Trans-Mucosal Nitrous Oxide Exchange for the Middle Ear.
    Teixeira MS; Alper CM; Martin BS; Helal N; Doyle BM; Doyle WJ
    Ann Otol Rhinol Laryngol; 2016 May; 125(5):400-7. PubMed ID: 26611245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical nasal decongestant oxymetazoline (0.05%) provides relief of nasal symptoms for 12 hours.
    Druce HM; Ramsey DL; Karnati S; Carr AN
    Rhinology; 2018 Dec; 56(4):343-350. PubMed ID: 29785414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying eustachian tube dysfunction prior to hyperbaric oxygen therapy: Who is at risk for intolerance?
    Cohn JE; Pfeiffer M; Patel N; Sataloff RT; McKinnon BJ
    Am J Otolaryngol; 2018; 39(1):14-19. PubMed ID: 29054767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.